Sonus shares surge as FDA approves Phase III design

Shares of Bothell, Washington-based Sonus Pharmaceuticals surged after the biotech announced that the FDA had approved its design for a Phase III trial of an experimental breast cancer therapy. The study will compare its Tocosol Paclitaxel against Taxol. Before the trial gets fully underway, though, Sonus needs to raise cash for the study.

"Our corporate development efforts are now focused on securing the necessary financial resources to support the study, and these efforts are ongoing on several fronts," said Michael A. Martino, President and CEO of Sonus. "In parallel, we have already begun to study start-up activities for the Phase 3 trial."

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.